ArticleFrontiers in immunology2025
The impact of pharmacists' interventions within the closed loop immunosuppressant management process on kidney transplant recipients: a retrospective cohort study.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact of clinical pharmacist-led medication management and education on tacrolimus therapeutic control.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nowadays, kidney transplant recipients' primary challenge is improving graft function. However, they are rarely provided effective long-term instructions on immunosuppressant use after transplant. This study aimed to describe the experiences of a pharmacist-led, closed-loop immunosuppressant service (PLIS) in the transplant center of a general hospital in China. Methods: A retrospective pre-and post-intervention study was conducted in the transplantation department in a general hospital. Of the 347 patients receiving kidney transplants from August 2022 to August 2024 were enrolled. Eligible subjects were assigned into two groups (pre-intervention group and post-intervention group) according to the date (1 August 2023) when the pharmacist commenced participation in the post-transplant management for kidney transplant recipients. The intra-patient variation in immunosuppressant trough concentrations (C Results: Among 347 patients (August 2022-2024), those managed post-intervention (from August 2023) showed improved target trough concentration (C Conclusion: PLIS enhanced immunosuppressant management precision and graft outcomes, demonstrating its utility in standardizing post-transplant care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.